This database contains 39 studies, archived under the term: "Neuroimaging (e.g. MRI, PET, CAT etc.)"
Click here to filter this large number of results.
Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy
Miyoshi, F.,
Ogawa, T.,
Kitao, S.- i.,
Kitayama, M.,
Shinohara, Y.,
Takasugi, M.,
Fujii, S.,
Kaminou, T.
Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late […]
Visuospatial memory and neuroimaging correlates in mild cognitive impairment
Mitolo, Micaela,
Gardini, Simona,
Fasano, Fabrizio,
Crisi, Girolamo,
Pelosi, Annalisa,
Pazzaglia, Francesca,
Caffarra, Paolo
Spatial abilities decline in normal aging and decrease faster and earlier in Alzheimer’s disease (AD), but these deficits are under investigated. The main goals of this study were to assess visuospatial memory abilities in mild cognitive impairment (MCI), in order to verify whether these tasks might be valid as the standard cognitive test to differentiate […]
Deep learning based imaging data completion for improved brain disease diagnosis
Li, Rongjian,
Zhang, Wenlu,
Suk, Heung-Il,
Wang, Li,
Li, Jiang,
Shen, Dinggang,
Ji, Shuiwang
Combining multi-modality brain data for disease diagnosis commonly leads to improved performance. A challenge in using multimodality data is that the data are commonly incomplete; namely, some modality might be missing for some subjects. In this work, we proposed a deep learning based framework for estimating multi-modality imaging data. Our method takes the form of […]
Altered microstructure in corticospinal tract in idiopathic normal pressure hydrocephalus: comparison with Alzheimer disease and Parkinson disease with dementia
Hattori, T.,
Yuasa, T.,
Aoki, S.,
Sato, R.,
Sawaura, H.,
Mori, T.,
Mizusawa, H.
Background and Purpose: Previous neuropathologic studies in chronic hydrocephalus have suggested the presence of white matter damage, presumably from mechanical pressure due to ventricular enlargement and metabolic derangement. This study aimed to investigate the diffusional properties of the CST in patients with iNPH by using DTI and to determine whether this method could be used […]
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline
Grundman, Michael,
Pontecorvo, Michael J.,
Salloway, Stephen P.,
Doraiswamy, P. Murali,
Fleisher, Adam S.,
Sadowsky, Carl H.,
Nair, Anil K.,
Siderowf, Andrew,
Lu, Ming,
Arora, Anupa K.,
Agbulos, Abigail,
Flitter, Matthew L.,
Krautkramer, Michael J.,
Sarsour, Khaled,
Skovronsky, Daniel M.,
Mintun, Mark A.
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]
Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer’s disease: utility in differential diagnosis
Colloby, Sean J,
Taylor, John-Paul,
Davison, Christopher M,
Lloyd, Jim J,
Firbank, Michael J,
McKeith, Ian G,
O'Brien, John T
We examined (99m)Tc-exametazime brain blood flow single-photon emission computed tomography (SPECT) images using a spatial covariance analysis (SCA) approach to assess its diagnostic value in distinguishing dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Voxel SCA was simultaneously applied to a set of preprocessed images (AD, n=40; DLB, n=26), generating a series of eigenimages […]
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests
Bahar-Fuchs, Alex,
Villemagne, Victor,
Ong, Kevin,
Chetélat, Gaël,
Lamb, Fiona,
Reininger, Cornelia B.,
Woodward, Michael,
Rowe, Christopher C.
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of […]
What predicts cognitive decline in de novo Parkinson’s disease?
Arnaldi, Dario,
Campus, Claudio,
Ferrara, Michela,
Famà, Francesco,
Picco, Agnese,
De Carli, Fabrizio,
Accardo, Jennifer,
Brugnolo, Andrea,
Sambuceti, Gianmario,
Morbelli, Silvia,
Nobili, Flavio
Subtle cognitive impairment can be detected in early Parkinson’s disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an […]